ENTITY
BeiGene

BeiGene (6160 HK)

309
Analysis
Health CareChina
BeiGene, Ltd. operates as a commercial stage biopharmaceutical company. The Company focuses on discovery, development, and commercialization of molecularly targeted and immuno-oncology drugs for the treatment of cancer. BeiGene serves patients worldwide.
more
Refresh
bearishMeituan
10 Sep 2018 05:50

Last Week in GER Research: Meituan, China Tower, Haidilao, Qutoutiao, Hua Med., Chunlai, and Cootek

Below is a recap of the key IPO research produced by the Global Equity Research team. This week we assess Meituan's latest results ahead of its...

Logo
323 Views
Share
bearishMeituan
03 Sep 2018 06:48

Last Week in GER Research: Meituan-Dianping, Nio, Gangfeng Lithium, Pinduoduo and 111 Inc

Below is a recap of the key IPO and fundamental research produced by the Global Equity Research team. This week we highlight a more palatable...

Logo
335 Views
Share
03 Sep 2018 06:28

Hua Medicine IPO Preview: Suffering from the Ascletis Over-Valuation Syndrome

Hua Medicine Ltd (2552 HK) which specialises in developing drugs to treat Type 2 diabetes, is the third pre-profit biotech firm to IPO in Hong Kong...

Logo
786 Views
Share
30 Aug 2018 14:31

Hua Medicine (华领医药) IPO: Little Upside to Fair Value

Hua Medicine launched the institutional book building today and intends to raise USD 111 to USD 124 million, with an implied market capitalization...

Logo
523 Views
Share
27 Aug 2018 06:05

Last Week in GER Research: Haidilao, Xiaomi, Ping An, 111, Qutoutiao, Nio and Tesla

Below is a recap of the key IPO and fundamental research produced by the Global Equity Research team. This week we highlight a differentiated...

Logo
355 Views
Share
x